EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tacrolimus treatment in reproductive failures

Koji Nakagawa, Yuji Orita, Keiji Kuroda, Rikikazu Sugiyama, Koushi Yamaguchi

Journal of Reproductive Immunology · 2026

DOI: 10.1016/j.jri.2025.104824 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Koji Nakagawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Japan. Electronic address: koji@sugiyama.ne.jp. Hauptthemen laut MEDLINE: Tacrolimus, Immunosuppressive Agents, Abortion, Habitual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Center for Child Health and Development, Rosalind Franklin University of Medicine and Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy for repeated implantation failure (RIF) following in vitro fertilization (IVF), particularly treatment with the calcineurin inhibitor tacrolimus-has now been used for roughly a decade since its initial report. In that initial series, the clinical pregnancy rate was 64.0 %; however, acceptance was slow. A recent re-evaluation at our center yields a similarly high clinical pregnancy rate of 57.1 %. In our earlier cohort, 37.7 % of RIF cases showed Th1/Th2 cell ratio suggestive of immune-mediated rejection; a more recent survey found a comparable proportion (35.9 %), indicating that approximately one-third of RIF may involve an immune component. Tacrolimus has also shown promise in immunologically mediated recurrent pregnancy loss (RPL), and its potential indications may extend to preventing obstetric complications such as abruptio placentae, hypertensive disorders of pregnancy (HDP), and HELLP syndrome. We summarize our experience, situate it within the evolving literature, and outline priorities for confirmatory trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusImmunosuppressive AgentsAbortion, HabitualHumansFemalePregnancyFertilization in VitroEmbryo Implantation

Stichwörter der Autor:innen

Hypertensive disorder of pregnancy (HDP)Preterm birth (PTB)Regulatory T (Treg) cellTacrolimusTh1/Th2 cell ratios

Substanzen

TacrolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Japan. Electronic address: koji@sugiyama.ne.jp.
  • Center for Reproductive Medicine and Endoscopy, Sugiyama Clinic Marunouchi, Tokyo, Japan.
  • Takeuchi Ladie's Clinic, Kagoshima, Japan.
  • Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Japan.
  • Department of Maternal-Fetal Biology, National Center for Child Health and Development, Tokyo, Japan.

Förderung

  • National Center for Child Health and Development
  • Rosalind Franklin University of Medicine and Science

Zitieren

APA

Nakagawa, K., Orita, Y., Kuroda, K., Sugiyama, R., & Yamaguchi, K. (2026). Tacrolimus treatment in reproductive failures. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2025.104824

Vancouver

Nakagawa K, Orita Y, Kuroda K, Sugiyama R, Yamaguchi K. Tacrolimus treatment in reproductive failures. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2025.104824

BibTeX
@article{Nakagawa2026,
  author = {Nakagawa, Koji and Orita, Yuji and Kuroda, Keiji and Sugiyama, Rikikazu and Yamaguchi, Koushi},
  title = {Tacrolimus treatment in reproductive failures},
  journal = {Journal of Reproductive Immunology},
  year = {2026},
  doi = {10.1016/j.jri.2025.104824}
}
Kostenlos starten →